Related Experiment Video

Updated: May 17, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

Inhibitors/antagonists of TGF-β system in kidney fibrosis

Motoko Yanagita

    Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
    |November 2, 2012
    PubMed

    Insights

    Transforming growth factor-beta (TGF-β) drives kidney fibrosis, a key indicator of chronic kidney disease. Targeting TGF-β shows promise, with bone morphogenetic protein 7 mimetics reversing fibrosis in models.

    Area of Science:

    • Nephrology
    • Fibrosis research
    • Molecular biology

    Background:

    • Renal fibrosis is a critical factor in chronic kidney disease progression and poor prognosis.
    • Transforming growth factor-beta (TGF-β) is a key mediator in renal fibrosis.
    • Systemic inflammation is a potential adverse effect of TGF-β inhibition due to its dual role.

    Discussion:

    • This review examines current literature on TGF-β inhibitors and antagonists for renal fibrosis.
    • It explores therapeutic strategies targeting TGF-β pathways.
    • Orally active bone morphogenetic protein 7 (BMP7) mimetics demonstrate efficacy in reversing established renal fibrosis.

    Key Insights:

    • TGF-β signaling is central to the development and progression of renal fibrosis.
    • Directly targeting TGF-β may carry risks of systemic inflammation.
    • BMP7 mimetics offer a potential therapeutic avenue with demonstrated success in preclinical models.

    Outlook:

    • Further research into selective TGF-β pathway modulation is warranted.
    • Clinical translation of BMP7 mimetics requires investigation.
    • Understanding the balance of TGF-β's pro-fibrotic and anti-inflammatory roles is crucial for future therapies.

    More Related Videos

    Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis04:37

    Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

    Published on: April 25, 2025

    Related Concept Videos

    TGF - β Signaling Pathway01:16

    TGF - β Signaling Pathway

    The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...